Tm Bioscience ready to consider sale or merger
This article was originally published in Clinica
Executive Summary
Tm Bioscience, the Toronto-based developer of DNA-based tests, says it would consider a sale or merger of its business as part of an exploration of ways to increase its value to shareholders. The company has appointed investment banks Leerink & Swann, of Boston, Massachusetts, and Westwind Partners, of Toronto, to help assess its options.